Therefore, further clinical studies are needed to verify whether therapies GLP-1 functional agonists could be used as supportive therapy to currently available antidepressant drugs or whether these compounds would have a beneficial effect in patients suffering from treatment-resistant depression [120]. This evidence concerns the gene GLP1R and depressive symptom measurement.